Monovisc Approval History
- FDA approved: Yes (First approved February 24th, 2014)
- Brand name: Monovisc
- Generic name: sodium hyaluronate
- Dosage form: Injection
- Company: Anika Therapeutics, Inc.
- Treatment for: Osteoarthritis
Monovisc (sodium hyaluronate) is a viscoelastic supplement indicated for the treatment of pain associated with osteoarthritis of the knee.
Development History and FDA Approval Process for Monovisc
|Feb 27, 2014||FDA Approves Monovisc, a New Single Injection Treatment for Pain Due to Osteoarthritis of the Knee|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.